GHRS vs. CSTL, RVNC, ATAI, DSGN, SGMO, FOLD, XENE, ARWR, PTCT, and DYN
Should you be buying GH Research stock or one of its competitors? The main competitors of GH Research include Castle Biosciences (CSTL), Revance Therapeutics (RVNC), Atai Life Sciences (ATAI), Design Therapeutics (DSGN), Sangamo Therapeutics (SGMO), Amicus Therapeutics (FOLD), Xenon Pharmaceuticals (XENE), Arrowhead Pharmaceuticals (ARWR), PTC Therapeutics (PTCT), and Dyne Therapeutics (DYN). These companies are all part of the "medical" sector.
Castle Biosciences (NASDAQ:CSTL) and GH Research (NASDAQ:GHRS) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their earnings, analyst recommendations, dividends, valuation, risk, community ranking, profitability, institutional ownership and media sentiment.
In the previous week, Castle Biosciences and Castle Biosciences both had 4 articles in the media. Castle Biosciences' average media sentiment score of 0.87 beat GH Research's score of 0.72 indicating that GH Research is being referred to more favorably in the news media.
GH Research has lower revenue, but higher earnings than Castle Biosciences. GH Research is trading at a lower price-to-earnings ratio than Castle Biosciences, indicating that it is currently the more affordable of the two stocks.
Castle Biosciences has a beta of 0.93, suggesting that its share price is 7% less volatile than the S&P 500. Comparatively, GH Research has a beta of 0.8, suggesting that its share price is 20% less volatile than the S&P 500.
GH Research has a net margin of 0.00% compared to GH Research's net margin of -12.28%. GH Research's return on equity of -7.91% beat Castle Biosciences' return on equity.
Castle Biosciences presently has a consensus price target of $31.57, suggesting a potential upside of 35.73%. GH Research has a consensus price target of $36.67, suggesting a potential upside of 160.23%. Given Castle Biosciences' higher probable upside, analysts clearly believe GH Research is more favorable than Castle Biosciences.
92.6% of Castle Biosciences shares are held by institutional investors. Comparatively, 56.9% of GH Research shares are held by institutional investors. 7.2% of Castle Biosciences shares are held by insiders. Comparatively, 41.6% of GH Research shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.
Castle Biosciences received 62 more outperform votes than GH Research when rated by MarketBeat users. However, 67.86% of users gave GH Research an outperform vote while only 62.31% of users gave Castle Biosciences an outperform vote.
Summary
Castle Biosciences beats GH Research on 8 of the 15 factors compared between the two stocks.
Get GH Research News Delivered to You Automatically
Sign up to receive the latest news and ratings for GHRS and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding GHRS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
GH Research Competitors List
Related Companies and Tools
